1. Testosterone replacement therapy of opioid-induced male hypogonadism improved body composition but not pain perception: a double-blind, randomized, and placebo-controlled trial
- Author
-
Emma Bendix, Marianne Andersen, Dorte Glintborg, Henrik Bjarke Vaegter, Per Grünwald Andersen, Thomas Graven-Nielsen, and Louise Lehmann Christensen
- Subjects
Male ,medicine.medical_specialty ,Hormone Replacement Therapy ,Endocrinology, Diabetes and Metabolism ,Placebo-controlled study ,Urology ,030209 endocrinology & metabolism ,Testosterone/therapeutic use ,Placebo ,Body Composition/drug effects ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Double-Blind Method ,Randomized controlled trial ,Quality of life ,law ,Internal medicine ,medicine ,Humans ,Testosterone ,Aged ,Analgesics, Opioid/adverse effects ,business.industry ,Hypogonadism ,Pain Perception ,General Medicine ,Middle Aged ,Pain Perception/drug effects ,Analgesics, Opioid ,Hormone Replacement Therapy/methods ,Hypogonadism/chemically induced ,Treatment Outcome ,Opioid ,Quartile ,030220 oncology & carcinogenesis ,Body Composition ,Quality of Life ,Lean body mass ,business ,medicine.drug - Abstract
Background Hypogonadism is prevalent during opioid treatment, but the effect of testosterone replacement treatment (TRT) on body composition, pain perception, and adrenal function is unclear. Purpose To measure changes in body composition, pain perception, quality of life, and adrenal function after TRT or placebo in opioid-treated men with chronic non-malignant pain. Methods Double-blind, placebo-controlled study in 41 men (>18 years) with total testosterone n = 20) or placebo (placebo-injections, n = 21). Outcomes Body composition (lean body mass and fat mass assessed by DXA), clinical pain intensity (numerical rating scale), and experimental pain perception (quantitative sensory assessment), quality of life (SF36), and adrenocorticotrophic hormone (ACTH) test. Data were presented as median (quartiles). Mann–Whitney tests were performed on delta values (24–0 weeks) between TRT and placebo. Results The median age was 55 years (46; 59) and total testosterone before intervention was 6.8 (5.0; 9.3) nmol/L. TRT was associated with change of testosterone levels: 12.3 (7.0; 19.9) nmol/L (P P Conclusions Six months of TRT improved body composition in men with opioid-induced hypogonadism without significant changes in outcomes of pain perception, quality of life, or adrenal function.
- Published
- 2020
- Full Text
- View/download PDF